Authors
Latest:
FDA approves niraparib/abiraterone tablet for BRCA-positive mCRPCThe approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.
Latest:
Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate CancerClosing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.
Latest:
Fluoroscopic Imaging and Other Developments in UrologyThe rationale for utilizing fluoroscopic imaging as well as other evolving technologies that are currently being developed and explored in urology.
Latest:
Urologic research and COVID-19: Unmasking the silver liningIn this column, the authors discuss how the coronavirus disease 2019 (COVID-19) shutdown yielded unexpected opportunities in urologic research.
Latest:
Worse rPFS, OS observed in patients with BRCA-mutated mCRPC vs non-BRCA“These results further support the importance of screening for germline and somatic BRCA1/2 alterations to deliver more precise care for our patient," says David Olmos, MD, PhD.
Latest:
Money Matters: Expert on why annuities are the “Swiss Army knife” of personal financeSocial Security benefits aren’t sufficient to fund retirement for most people. And given the aging of the population and projected trust-fund shortfall, they may be less generous in the future.
Latest:
Perioperative cabozantinib shows promise in metastatic kidney cancerPerioperative treatment with cabozantinib is feasible with early signs of clinical activity in patients with intermediate- and poor-risk metastatic renal cell carcinoma.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
Despite overall gains, leadership and payment gaps remain for women in medicine"The good news is that women have been entering medicine in increasing numbers for more than three decades. The not-so-good news is that women are still underrepresented and underutilized in positions of power," writes Deborah M. Shlian, MD, MBA.
Latest:
EP. 4B: Educating Patients on Their Treatment Options for LG UTUCIn this companion article, Armine K. Smith, MD, reflects on the role of kidney-sparing approaches for LG UTUC and emphasizes the importance of patient-provider communication when making treatment decisions.
Latest:
Expert insight on ransomware: Is your practice prepared?Ransomware has never been a more serious threat for health care organizations, even small medical practices.
Latest:
Closing Thoughts on Urology Practice Management and Treatment of Advanced Prostate CancerClosing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.
Latest:
How APPs can be involved with genitourinary cancer careA nurse practitioner discusses how she supports multiple providers in a large academic practice.
Latest:
Moving transperineal prostate biopsy into the clinicLearning curve for technique is short, but capital expenditures are required.
Latest:
Expert Opinion: We cannot continue to ignore the problem of physician mental distress"We need health systems, state medical boards and physician employment settings to commit to prioritizing physician wellbeing and provide the reassurances and resources that encourage physicians in need to seek help," writes Russell Libby, MD.
Latest:
Survey shows significant impact of billing process on patients’ choice of providerAlthough traditional payment and communication methods remain relevant, the survey highlights a paradigm shift in patients' billing expectations overall.
Latest:
Novel dual agents for advanced prostate cancerA recap of presentations from AUA 2021 highlighting next steps using novel therapies as combination approaches to treat advanced prostate cancer.
Latest:
Study shows promise of immunotherapy treatment for penile cancer“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.
Latest:
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular RecurrenceDr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
Latest:
MRI-based screening emerging as viable alternative to PSA testing“MRI-based screening showed lower proportions of screening-positive cases, lower false positive rates, and higher PPVs [positive predictive values] than those of PSA-based screening,” noted Taek Min Kim, MD.
Latest:
Is greater patient control of their personal health records a plus for physicians?The Cures Act has teeth and consumers are becoming increasingly aware of their right to obtain their information.
Latest:
Moffitt study shows genomic testing can identify African American prostate cancer patients with high-risk diseaseMoffitt Cancer Center conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer
Latest:
Emulating target trials using observational evidence to inform clinical decision-making"The emulation framework lends the design and conduct of observational analyses some of the rigor required for the planning of a randomized trial. In doing so, it provides an innovative and principled approach to improve the evidence base on the comparative effectiveness of interventions," writes Boris Gershman, MD, and Aaron Fleishman, MPH.
Latest:
Survey shows high mistreatment rates among women, minority groups in academic medicineThe findings of harassment and inappropriate behavior come at a time when there is widespread agreement among health care leaders about the need for a more diverse physician workforce.
Latest:
Urology Perspective on Radiation Toxicity in Prostate CancerUrologists offer their perspectives on toxicity seen in patients with prostate cancer who are undergoing radiation treatment.
Latest:
Can remote patient monitoring help combat the staffing shortage?"As more patients become interested in remote patient monitoring and case studies continue to show improved patient outcomes, practices must seek ways to integrate these tools into their workflows," writes Lucienne Marie Ide, MD, PhD.
Latest:
Unmet Needs and Investigational Therapies in mCSPCDr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Chronic care management in the urologic oncology settingCCM programs can engage multiple providers to care for patients while reducing in-person visits.
